Novelty Nobility, a Korean antibody drug discovery company, said Monday that it has been selected to join JLABS Korea, part of Johnson & Johnson’s global incubator network.

JLABS is a global open innovation platform that supports and accelerates startups by providing access to expertise, development resources, strategic partnerships, and investor networks across the entire healthcare spectrum, including pharmaceuticals and medtech.

Through JLABS Korea, Novelty Nobility will focus on developing NN4101, a bispecific antibody candidate targeting c-Kit and VEGF for vascular retinal diseases, and NN3206, an antibody-drug conjugate (ADC) candidate targeting Pan-RAS-mutated solid tumors.

The company specializes in advanced modality antibody drugs, such as bispecific antibodies and ADCs, based on its proprietary fully human antibody platform. Its pipeline targets therapeutic areas well-suited to antibody treatments, including immune disorders, cancer, and ophthalmic diseases.

In July of last year, Novelty Nobility received A and A grades from two different institutions in the technical evaluation for a special listing on Kosdaq, and has recently filed a preliminary listing application.

“We will actively leverage JLABS Korea to enhance the competitiveness of our early-stage follow-on pipeline in the global market,” said Park Sang-gyu, CEO of Novelty Nobility. “We are committed to advancing our pipeline and achieving meaningful business outcomes through collaborative research with global pharmaceutical companies.”